Point of care assessment of melanoma tumor signaling and metastatic burden from ?NMR analysis of tumor fine needle aspirates and peripheral blood.
Related Articles Point of care assessment of melanoma tumor signaling and metastatic burden from ?NMR analysis of tumor fine needle aspirates and peripheral blood.
Nanomedicine. 2017 Apr;13(3):821-828
Authors: Gee MS, Ghazani AA, Haq R, Wargo JA, Sebas M, Sullivan RJ, Lee H, Weissleder R
Abstract
This study evaluates ?NMR technology for molecular profiling of tumor fine needle aspirates and peripheral blood of melanoma patients. In vitro assessment of melanocyte (MART-1, HMB45) and MAP kinase signaling (pERK, pS6K) molecule expression was performed in human cell lines, while clinical validation was performed in an IRB-approved study of melanoma patients undergoing biopsy and blood sampling. Tumor FNA and blood specimens were compared with BRAF genetic analysis and cross-sectional imaging. ?NMR in vitro analysis showed increased expression of melanocyte markers in melanoma cells as well as increased expression of phosphorylated MAP kinase targets in BRAF-mutant melanoma cells. Melanoma patient FNA samples showed increased pERK and pS6K levels in BRAF mutant compared with BRAF WT melanomas, with ?NMR blood circulating tumor cell level increased with higher metastatic burden visible on imaging. These results indicate that ?NMR technology provides minimally invasive point-of-care evaluation of tumor signaling and metastatic burden in melanoma patients.
PMID: 27993725 [PubMed - indexed for MEDLINE]
More...